{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T13:10:04Z","timestamp":1715951404406},"reference-count":16,"publisher":"Informa UK Limited","issue":"5","funder":[{"name":"The Pharmaceutical Research and Manufacturers of America"},{"name":"e biopharmaceutical sector and related industries"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Personalized Medicine"],"published-print":{"date-parts":[[2011,9]]},"DOI":"10.2217\/pme.11.51","type":"journal-article","created":{"date-parts":[[2011,9,9]],"date-time":"2011-09-09T22:24:25Z","timestamp":1315607065000},"page":"541-550","source":"Crossref","is-referenced-by-count":1,"title":["Biopharmaceutical Industry Perspectives on the Business Prospects for Personalized Medicine"],"prefix":"10.1080","volume":"8","author":[{"given":"Christopher-Paul","family":"Milne","sequence":"first","affiliation":[{"name":"Tufts Center for the Study of Drug Development, Tufts University Medical School, 75 Kneeland St., Suite 1100, Boston, MA02111,USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachael","family":"Zuckerman","sequence":"additional","affiliation":[{"name":"Bloomberg School of Public Health, The Johns Hopkins University, Baltimore, MD, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2011,9,9]]},"reference":[{"key":"e_1_3_3_3_1_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2010.230"},{"issue":"6","key":"e_1_3_3_3_2_1","volume":"12","author":"Kaitin K","year":"2010","unstructured":"Kaitin K . Personalized medicine is playing a growing role in development pipelines. Tufts Center for the Study of Drug Development Impact Report.12(6) , (2010).","journal-title":"Tufts Center for the Study of Drug Development Impact Report."},{"issue":"12","key":"e_1_3_3_3_3_1","first-page":"670","volume":"35","author":"Vogenberg RF","year":"2010","unstructured":"Vogenberg RF , BarashCI, PurselM. Challenges facing health care plans in implementing coverage policies for pharmacogenomic and genetic testing. P. T.35(12) , 670\u2013675 (2010).","journal-title":"P. T."},{"issue":"8","key":"e_1_3_3_3_4_1","first-page":"577","volume":"11","author":"Schulman KA","year":"2009","unstructured":"Schulman KA , VidalAV, AckerlyCD. Personalized medicine and disruptive innovation: Implicat. Tech. Asses. Gene. Med.11(8) , 577\u2013581 (2009).","journal-title":"Implicat. Tech. Asses. Gene. Med."},{"key":"e_1_3_3_3_5_1","unstructured":"Christiensen CM\n. The Innovator\u2018s Dilemma . Harvard Bus. School Press Boston MA USA (1997)."},{"issue":"1","key":"e_1_3_3_3_6_1","first-page":"59","volume":"10","author":"Ferrara J","year":"2007","unstructured":"Ferrara J . Personalized medicine: challenging pharmaceutical and diagnostic company business models. Mcgill J. Med.10(1) , 59\u201361 (2007).","journal-title":"Mcgill J. Med."},{"issue":"11","key":"e_1_3_3_3_7_1","first-page":"546","volume":"17","author":"Valenti WM","year":"2007","unstructured":"Valenti WM . Companion diagnostic tests in HIV medicine: the road to personalized medicine. AIDS Reader17(11) , 546\u2013549 (2007).","journal-title":"AIDS Reader"},{"key":"e_1_3_3_4_2_1","unstructured":"The Case for Personalized Medicine Personalized Medicine Coalition (PMC) www.personalizedmedicinecoalition.org\/about\/about-personalized-medicine\/the-case-for-personalized-medicine"},{"key":"e_1_3_3_4_3_1","unstructured":"Naylor S Cole T. Overview of companion diagnostics in the pharmaceutical industry 2010 www.ddw-nline.com\/personalised_medicine\/580044\/ (Accessed 13April2011)"},{"key":"e_1_3_3_4_4_1","unstructured":"Lester DS. Will personalized medicine help in transforming the business of healthcare www.medscape.com\/viewarticle\/712541."},{"key":"e_1_3_3_4_5_1","unstructured":"Esoterix Inc. Companion diagnostics for guiding therapy decisions: bridging the gap from development to commercialization http:\/\/ngpharma.com\/article\/ (Accessed 13April2011)"},{"key":"e_1_3_3_4_6_1","unstructured":"Gustavsen G Phillips K Pothier K for Health Advances LLC The Reimbursement Landscape for Novel Diagnostics: Current Limitations Real-World Impact and Proposed Solutions 13\u201319 25 (2010) www.healthadvances.com (Accessed 4April2011)"},{"key":"e_1_3_3_4_7_1","unstructured":"Maas A. More plans are mandating genetic tests for some specialty therapies Health Business Daily February 2011 http:\/\/aishealth.com\/archive\/nspn0211-05"},{"key":"e_1_3_3_4_8_1","unstructured":"Hutton D. Two are better than one drug discovery news October 2010 www.drugdiscoverynews.com\/print.php?newsarticle=4229 (Accessed 13April2011)"},{"key":"e_1_3_3_4_9_1","unstructured":"Konski AF. Legal challenges to healthcare reform threaten biopharmaceutical legislation genetic engineering and biotechnology news March 29 2011 www.genengnews.com\/keywordsandtools\/print\/3\/22475\/ (Accessed 4April2011)"},{"key":"e_1_3_3_4_10_1","unstructured":"Usdin S. PDUFA: a lot of talk June 6 2011 www.biocentury.com\/biotech-pharma-news (Accessed June 20 2011)"}],"container-title":["Personalized Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/pme.11.51","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T12:55:04Z","timestamp":1715950504000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/pme.11.51"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,9]]},"references-count":16,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2011,9]]}},"alternative-id":["10.2217\/pme.11.51"],"URL":"https:\/\/doi.org\/10.2217\/pme.11.51","relation":{},"ISSN":["1741-0541","1744-828X"],"issn-type":[{"value":"1741-0541","type":"print"},{"value":"1744-828X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,9]]}}}